Holy Cross 9th Annual Winter Oncology Symposium
Avatar

Genetic Testing in Breast and Ovarian Cancer: BRCA1/2 and PARP Inhibitors

By Holy Cross 9th Annual Winter Oncology Symposium FEATURING Delia Constanza Guaqueta
By Holy Cross 9th Annual Winter Oncology Symposium FEATURING Delia Constanza Guaqueta
1,049 views
March 20, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
09:19
Insights from 2023 SABCS

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for…

Feat. K. Kalinsky
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
07:23
Total Health

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Feat. R. O'Regan
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
06:07
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Feat. M. Raza Mirza
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
06:50
Fengting Yan

Year in Review: Ovarian Cancer

11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar
08:48
James Martin

2L Therapy for ER+ mBC Following CDK4/6i

25:10
Yale School of Medicine

Ovarian Cancer Prevention and Early Detection - Ovarian Cancer Does …

Feat. M. Minkin, E. Ratner